Biogen MA sues USPTO Director for extra 23 days in term of human anti-tau antibodies patent

What is 23 days worth to you? Pharmaceutical giant Biogen MA is suing Andrei Iancu, the director of the U.S. Patent and Trademark Office, to force the PTO to extend a patent for Human Anti-Tau Antibodies for an extra 23 days because of an alleged improper calculation of delays in the approval of the patent. [...]

By | February 15th, 2018|drug patents, litigation, Patent Investing, USPTO|0 Comments

Trump and the GOP’s focus on how IP affects drug prices, China IP theft, ignores how much U.S. patents have been weakened

Intellectual property issues are taking on new prominence in Washington, D.C., with the Senate scheduled to vote on the nomination of Andrei Iancu as the undersecretary of commerce and director of the U.S. Patent and Trademark Office, on Monday, Feb. 5 and President Donald Tump signaling his top IP priority in last night’s state of [...]

(Update2) Judge invalidates Allergan’s Restasis patents, raises serious questions about sovereign immunity strategy

Judge William Bryson of the U.S. District Court in Marshall, Texas on Monday invalidated the patents for Allergan Plc’s dry eye treatment Restasis allowing generic drug makers to produce their own versions of the drug and raised serious questions about the pharmaceutical company’s attempt to rent the sovereign immunity of the Saint Regis Mohawk Tribe. [...]

By | October 17th, 2017|drug patents, litigation, Patent Investing, PTAB|0 Comments

Spherix acquires Hoth Therapeutics, becoming latest licensing company to acquire product company

Spherix Inc. (SPEX), which turned over its enforcement actions to Equitable IP Holdings Corp., acquired Hoth Therapeutics, a developmental stage company focused on treatments for atopic dermatitis such as eczema. The Bethesda, Maryland-based company didn’t say how much it paid but in acquiring Hoth Therapeutics Spherix became the latest patent licensing company to use its [...]

By | June 21st, 2017|drug patents, Patent Investing, Product|0 Comments

PTAB invalidates key claims of patent supporting Valeant’s Apriso drug for ulcerative colitis

The Patent Trial and Appeal Board on May 19 invalidated the only two independent claims of a patent supporting Valeant Pharmaceuticals International Inc. (VRX)’s drug Apriso, which is a treatment for maintenance of remission of ulcerative colitis and is expected to produce about $120 million in earnings before income tax depreciation and amortization in 2018. [...]

By | May 24th, 2017|drug patents, Patent Investing, PTAB|0 Comments

Bayer and Janssen file infringement action against Taro after it seeks FDA permission to produce a generic version of anti blood clot drug Xarelto

Bayer Intellectual Property GmbH, Bayer AG and Janssen Pharmaceuticals filed a patent infringement action against Taro Pharmaceutical Industries Ltd. and its U.S. subsidiary Taro Pharmaceuticals U.S.A. Inc. alleging infringement of a patent related to Xarelto, a drug that treats blood clots. The action filed in U.S. District Court in Wilmington, Delaware, arises out of the submission [...]

By | April 25th, 2017|drug patents, litigation, Patent Investing|0 Comments

Johnson & Johnson said to get more than 3,000 patents with $30B acquisition of Actelion

Johnson & Johnson (JNJ), the healthcare giant run by CEO Alex Gorsky, said yesterday it was acquiring Swiss pharmaceutical company Actelion Ltd. (ATLN) for $30 billion in stock, in a deal IP advisory firm Dominion Harbor Group said may add more than 3,000 patents and patent applications to Johnson & Johnson’s arsenal. New Brunswick, New [...]

By | January 27th, 2017|drug patents, Patent Investing|0 Comments

Biogen agrees to pay Forward Pharma $1.25B for license to all of the Danish company’s IP

Biogen Inc. (BIIB), the biotech giant run by CEO Michel Vounatsos, said on Tuesday, Jan. 17, it agreed to enter into a settlement and license agreement with Forward Pharma A/S, subject to the approval of Forward Pharma’s shareholders and other customary conditions. The Cambridge, Massachusetts company said the license agreement will provide Biogen an irrevocable [...]

(Update1) Hayman Capital’s Bass sees Trump as ally in his campaign against invalid drug patents and high drug prices

J. Kyle Bass, the founder and chief investment officer of Hayman Capital Management, is hoping the Coalition for Affordable Drugs, the group he runs with IP Navigation Group founder Erich Spangenberg to challenge weak or invalid drug patents, has a new ally in President-elect Donald Trump. Trump, who complained on the campaign trail about runaway [...]

By | December 13th, 2016|drug patents, Patent Investing|0 Comments